B Sun

Abstract

Surfactant replacement and inhaled nitric oxide are two important respiratory therapies for neonatal respiratory distress and persistent pulmonary hypertension. However, limitation of each therapy alone in various respiratory disorders raised questions as to whether we should use them in a combined manner, or in combination with other effective treatment modalities, so that the problems in both alveolar space and intrapulmonary vasculature may well be dealt with simultaneously. In recent years, a number of experimental and clinical studies have demonstrated that combined surfactant and inhaled nitric oxide consistently showed better effects than that of the independent therapy, suggesting that the adequate use of these two therapies may have a potential to improve clinical management of severe respiratory problems in infants and children.

肺表面活性物替代物與吸入一氧化氮是新生兒呼吸窘迫症和持續性肺動脈高壓症的兩種重要的治療方法。然而在多種呼吸系統疾病治療中單獨應用其中一種療法的療效並不充分。那麼，能否將上述兩種治療方法聯合應用，或與其他有效治療模式聯合應用，使肺泡膨脹性與肺內血管兩者的異常同時得到治療呢？近年來許多實驗與臨床研究已經証明同時應用肺表面活性物與吸入一氧化氮較單獨應用療效更好，提示恰當應用這兩種治療可能增進臨床治療嬰兒與兒童嚴重呼吸障礙的療效。